seed
Stage
About
KyDo Therapeutics GmbH is a preclinical-stage biotechnology company developing novel covalent-allosteric small-molecule inhibitors targeting AKT-driven cancers, including glioblastoma, advancing their lead programs toward IND-enabling studies.
Explore KyDo Therapeutics GmbH's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.